Skip to main content

Table 2 Biodistribution of 18 F-FDG in mice bearing A431 tumors

From: Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression

Tissue 18F-FDG uptake level ((%ID/g)×kg)
Control Gefitinib 100 Gefitinib 200
n = 8 n = 7 n = 7
Blood 0.046 ± 0.027 0.032 ± 0.019 0.037 ± 0.015
Tumor 0.129 ± 0.045 0.112 ± 0.023 0.111 ± 0.023
Muscle 0.022 ± 0.005 0.020 ± 0.007 0.020 ± 0.005
Heart 0.648 ± 0.587 0.709 ± 0.467 0.526 ± 0.587
Brown fat 0.372 ± 0.182 0.241 ± 0.090 0.290 ± 0.187
Lung 0.108 ± 0.017 0.100 ± 0.010 0.100 ± 0.010
Brain 0.171 ± 0.028 0.156 ± 0.020 0.172 ± 0.033
Spleen 0.115 ± 0.014 0.103 ± 0.013 0.113 ± 0.015
Liver 0.071 ± 0.033 0.055 ± 0.026 0.058 ± 0.018
Kidney 0.168 ± 0.029 0.122 ± 0.050 0.124 ± 0.036
Skin 0.162 ± 0.030 0.136 ± 0.042 0.149 ± 0.024
Tumor/muscle ratio 5.8 ± 1.4 5.9 ± 1.5 5.6 ± 1.1